Interfering with long chain noncoding RNA ANRIL expression reduces heart failure in rats with diabetes by inhibiting myocardial oxidative stress

Dai, Wei; Lee, Dongwon

doi:10.1002/jcb.29162

Cited by 23 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Down‐regulated lncRNA‐GASL1 in CHF regulated cardiomyocyte apoptosis 51 . Interfering of lncRNA ANRIL reduces heart failure in rats with diabetes by inhibiting myocardial oxidative stress 52 . Lnc‐NOS2P3, the pseudogene 3, localizes in the same chromosome 17 neighbouring iNOS (NOS2).…”

Section: Discussionmentioning

confidence: 99%

Differentially expressed lnc‐NOS2P3‐miR‐939‐5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNFα pathway

Chen

Zong

Lü

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

As more and more patients survive their initial cardiovascular diseases, chronic heart failure (CHF) becomes the leading cause of elderly hospitalization and death worldwide. 1 Therapeutic strategies improvements didn't increase CHF survival rate effectively. 2 CHF is a progressive disease, and the critical pathogenesis is myocardial pathological remodelling, initially triggered by multiple signal and network interactions 3 including overactivation of many neurohormones and inflammation factors after myocardial injury. 4,5 CHF is classified into four grades

show abstract

Section: Discussionmentioning

confidence: 99%

Differentially expressed lnc‐NOS2P3‐miR‐939‐5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNFα pathway

Chen

Zong

Lü

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…In a murine model, silencing the expression of ANRIL (antisense lncRNA in the INK4 locus) improved the maladaptive myocardial remodelling and reduced the expression of inflammatory factors in ischaemic myocardial tissue of diabetic rats, by inhibiting myocardial oxidative stress [86,87].…”

Section: Long Noncoding Rna and Hfmentioning

confidence: 99%

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective

Biasucci

Maino

Grimaldi

et al. 2021

JCM

View full text Add to dashboard Cite

Heart failure (HF) is a complex clinical syndrome with a huge social burden in terms of cost, morbidity, and mortality. Brain natriuretic peptide (BNP) appears to be the gold standard in supporting the daily clinical management of patients with HF. Novel biomarkers may supplement BNP to improve the understanding of this complex disease process and, possibly, to personalize care for the different phenotypes, in order to ameliorate prognosis. In this review, we will examine some of the most promising novel biomarkers in HF. Inflammation plays a pivotal role in the genesis and progression of HF and, therefore, several candidate molecules have been investigated in recent years for diagnosis, prognosis, and therapy monitoring. Noncoding RNAs are attractive as biomarkers and their potential clinical applications may be feasible in the era of personalized medicine. Given the complex pathophysiology of HF, it is reasonable to expect that the future of biomarkers lies in the application of precision medicine, through wider testing panels and “omics” technologies, to further improve HF care delivery.

show abstract

“…Although the direct impact of these variants in human tissue or animal models is difficult to discern, work with mutations of ANRIL in endothelial models have provided valuable insight. Specifically, upregulation of ANRIL has been associated with increased expression of inflammatory and oxidative markers in the vascular tissue such as IL-6, IL-8, NF-κB, TNF-a, iNOS, ICAM-1, VCAM-1, and COX-2 (130,131). These observations provide vital information about cellular mechanisms impacted by human disease-associated genetic risk factors without requiring the expense and time investment of creating, validating, and studying animal models.…”

Section: Modeling Of Human Genomic Discoveriesmentioning

confidence: 99%

Translational Genomics in Neurocritical Care: a Review

2020

View full text Add to dashboard Cite

Translational genomics represents a broad field of study that combines genome and transcriptome-wide studies in humans and model systems to refine our understanding of human biology and ultimately identify new ways to treat and prevent disease. The approaches to translational genomics can be broadly grouped into two methodologies, forward and reverse genomic translation. Traditional (forward) genomic translation begins with model systems and aims at using unbiased genetic associations in these models to derive insight into biological mechanisms that may also be relevant in human disease. Reverse genomic translation begins with observations made through human genomic studies and refines these observations through follow-up studies using model systems. The ultimate goal of these approaches is to clarify intervenable processes as targets for therapeutic development. In this review, we describe some of the approaches being taken to apply translational genomics to the study of diseases commonly encountered in the neurocritical care setting, including hemorrhagic and ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, and status epilepticus, utilizing both forward and reverse genomic translational techniques. Further, we highlight approaches in the field that could be applied in neurocritical care to improve our ability to identify new treatment modalities as well as to provide important information to patients about risk and prognosis.

show abstract

Interfering with long chain noncoding RNA ANRIL expression reduces heart failure in rats with diabetes by inhibiting myocardial oxidative stress

Cited by 23 publications

References 36 publications

Differentially expressed lnc‐NOS2P3‐miR‐939‐5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNFα pathway

Differentially expressed lnc‐NOS2P3‐miR‐939‐5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNFα pathway

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective

Translational Genomics in Neurocritical Care: a Review

Contact Info

Product

Resources

About